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Background/Aims
Antispasmodics including otilonium bromide (OB) are recommended to treat irritable bowel syndrome (IBS). However, reports 
about OB experience in Asia is sparse. The purpose of present study was to provide the efficacy of OB in treating Asian IBS 
patients.
Methods
Overall, 117 IBS patients meeting Rome II criteria were enrolled in an 8-week, double-blind, active-controlled and single center 
trial. Randomized participants received either OB 40 mg or mebeverine 100 mg 3 doses daily. The primary endpoints were to 
evaluate the net changes of abdominal pain/discomfort frequency score (APDFS) and safety profile, while the secondary end-
points were to assess the changes in abdominal pain/discomfort intensity, flatulence, abdominal bloating, satisfied stool fre-
quency etc.
Results
Finally, 49 OB and 52 mebeverine subjects were eligible for efficacy analysis. Compared to baselines in per protocol pop-
ulations, the reduced APDFSs in OB and mebeverine were 0.55 ± 1.20 (P = 0.011) and 0.37 ± 1.11 (P = 0.042), re-
spectively, to show similarly reduced scores. The most reported side effects included dry mouth, nausea and dizziness. Besides, 
the improved APDFSs at 4th week visit, final alleviations in abdominal pain intensity, flatulence, abdominal bloating and sat-
isfied stool frequency with global assessments filled by both patients and investigators were significantly achieved by both 
treatments, and OB was not inferior to mebeverine in treating these parameters.
Conclusions
In Orientals, OB is as effective as mebeverine for alleviating IBS symptoms in terms of abdominal pain, flatulence, abdominal 
bloating etc. However, obvious side effects are also observed. A large-scaled trial and post-marketing surveillance are recom-
mended to confirm its efficacy and safety.
(J Neurogastroenterol Motil 2011;17:402-410)
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Introduction
Irritable bowel syndrome (IBS) refers to a functional gastro-
intestinal (GI) disorder characterized by the abdominal pain/dis-
comfort that is associated with disturbed bowel movement (BM) 
in terms of stool frequency and consistency.
1,2 Currently, the true 
IBS pathophysiology remains enigmatic since many mechanisms 
have been addressed but not well agreed. For example, the most 
mentioned mechanisms include GI dysmotility, autonomic nerv-
ous dysfunction, visceral hypersensitivity, gut immune dysfunc-
tion, neuropeptide receptor dysfunction, brain-gut dysfunctional 
linkage, genetic polymorphism, psychological disorders etc.
3-7 
Clinically, IBS per se has a profound impact on the living and 
quality of life leading to the excessive use of medical resour-
ces.
2,8-10 The up-to-date IBS treatment strategy recommends a 
positive diagnosis, consideration of the patients’ agenda and emo-
tional state, continuous care and evaluations on graded ther-
apeutic responses.
1,3,6,10,11 Unfortunately, many available treat-
ments are not globally agreed and accepted between countries, 
medical payers and patients, while IBS subjects are often not sat-
isfactory to those treatments.
5,11,12 Newly developed drugs tar-
geted on receptors are emerging, however, current IBS guide-
lines still recommend antispasmodics in diminishing pain/dis-
comfort severity although these agents have been launched for 
decades.
2,3,5,6,10,13 Meta-analysis indicates again that smooth mus-
cle relaxants are effective in reducing abdominal pain and global 
symptom compared to the placebo.
14
Among the antispasmodics, otilonium bromide (OB) is claim-
ed to reduce the IBS pain severity effectively.
3,10,12 Pharmacologi-
cally, OB is one of the quaternary ammonium derivatives with GI 
smooth muscle spasmolytic activity via inhibition of calcium ion 
influx through L-type voltage operated calcium channels.
15,16 
European studies already confirmed OB in relieving IBS 
pain/discomfort.
17,18 Interestingly, reports on its experiences in 
Asia are not existed. Therefore, we conducted a single center, 
double-blind, randomized, active drug-controlled trial in looking 
its efficacy. The primary endpoints were to evaluate the improve-
ment of abdominal pain/discomfort frequency score (APDFS) 
and drug safety under an 8-week OB treatment. The secondary 
endpoints were to assess the OB efficacies by (1) the net change 
of the 4th week evaluation compared to the baseline APDFS, (2) 
the net change of the 8th week evaluation compared to the base-
line abdominal pain/discomfort intensity severity, (3) the changes 
of other IBS parameters including flatulence, abdominal bloating 
and satisfied stool frequency and (4) the global assessments after 
treatment filled by both the investigators and patients.
Materials and Methods
Enrolled Subjects
This study was conducted between November 2003 and 
January 2006. Briefly, eligible subjects aging 20-80 year who pre-
sented with bowel symptoms fulfilling Rome II criteria in the 
Outpatient Department of Taipei Veterans General Hospital 
were consecutively invited and considered to participate in this 
trial.
19 Alarm symptoms and signs such as fever, bloody stool, 
persistent diarrhea, marked body weight loss and anemia were 
excluded. Colon imaging study using either barium enema or co-
lonoscopy within the previous year should be normal in the sub-
jects (age ≥ 40 years). Other criteria of exclusion included preg-
nant or breastfeeding women, history of malignancy within 5 
years, gut surgery except appendectomy, malabsorption diseases, 
hyper- or hypothyroidism, abnormal renal or liver function tests, 
inflammatory bowel diseases, connective tissue diseases, severely 
progressive diseases, diabetes, obvious psychiatric disorders, sub-
stance abuse, unable to discontinue drugs known to influence gut 
motility, using iron supplements or colchicine, concurrently par-
ticipating in another study etc. This study was approved by the 
Institutional Review Board of Taipei Veterans General Hospital 
and Department of Health, ROC, while informed consent was 
obtained from all participants prior to the recruitment. 
Study Design
This study was designed as a double-blind, randomized, par-
allel and comparative trial. We expected to assign about 40 as-
sessable subjects to each of 2 study arms. Under consideration of 
probable withdrawal, at least 100 IBS subjects (50 in each arm) 
were planned to enroll. During the screening visit (14 days prior 
to the first treatment day), demographic data, vital signs, general 
physical examinations, concomitant medications, medical history, 
concurrent diseases, laboratory and pregnancy tests and current 
IBS symptoms were obtained. After this visit, all the prohibited 
drugs were held at least 1 week prior to the randomization. On 
day 1 of visit 2, treatment assignment was based on pre-generated 
permuted block randomization scheme. The block size of four 
was used to enroll subjects with a 1:1 ratio of the OB arm to con-
trolled mebeverine arm. Clinical evaluation was performed again 
to confirm the eligibility and to record the IBS symptomatic Full-Young Chang, et al
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baselines. After randomization, the eligible subjects were pro-
vided with a patient diary record and were treated using either 
OB or mebeverine for a total of 8 weeks in a double-blind 
method. They were instructed to come back for the 3rd visit at 
the end of 4th week (within ± 5 days treatment window) after 
randomization. Similar clinical evaluation was performed to as-
sess their treating efficacy and safety. Patient’s diary record was 
collected and a new card was given again. Unused study medi-
cations were collected to document drug accountability. Each 
subject was prescribed with the similarly coded medications for 
another 4-week treatment period. Final visit was performed at the 
end of 8th week after randomization. The efficacy and adverse 
events were recorded again. The global assessments filled by the 
investigators and patients were acquired. Consumption of con-
comitant medications during the entire study period was 
documented. Laboratory and pregnancy tests were repeated to 
confirm the study safety.
Study Drugs and Rescue Agents
A double-blind and double-dummy method was used in this 
study to achieve the double masking. For instance, OB active 
tablet (40 mg, batch no. ML157011; YL115128/YL115129) 
and its matching placebo tablet were prepared to be identical in all 
aspects. While mebeverine HCl active tablet (100 mg, bath no. 
310991) and its matched placebo tablet were similarly manufac-
tured to be unidentifiable. Subjects in the OB arm were in-
structed to consume one tablet of OB plus 1 tablet of mebeverine 
placebo simultaneously 3 times daily 30 minutes before the meals. 
Subjects assigned to the mebeverine arm were instructed to con-
sume one mebeverine tablet plus one OB placebo tablet 3 times 
daily before the meals. All the study products and placebo were 
supplied under the responsibility of TTY Biopharm Co, Ltd 
(Taipei, Taiwan). The frequency to supply study drugs to the 
study site was adapted to the expiry date of products. Rescue 
agent such as loperamide one tablet daily was allowed to the sub-
ject who suffered from intractable diarrhea (＞ 3/day for 3 days) 
during the trial. On the other hand, bisacodyl 2 tablets daily was 
allowed for subject who suffered from annoying constipation (no 
BM ＞ 3 days).
Symptomatic Assessments and Safety Record-
ing
The primary efficacy variable was to measure the change in 
APDFS after 8 weeks of treatment. Based on the diary card, the 
APDFS was categorized into four grades: score 0 = none; score 
1 = ≤ 3 episodes per week; score 2 = 4-7 episodes per week; 
and score 3 = ＞ 7 episodes per week. The APDFS scored at 
visit 2 served as baseline and was re-evaluated at the ends of 4th 
and 8th week after treatment, respectively. The abdominal 
pain/discomfort intensity was subjectively scored into four cate-
gories: score 0 = absent; score 1 = mild; score 2 = moderate; 
and score 3 = severe. Besides, a 10 cm visual analog scale (VAS) 
to record grades of flatulence, abdominal bloating and satisfied 
stool frequency by the subjects was instructed by oral and written 
information before the assessment. The 0 cm end means “no 
symptom” or “normal,” whereas the 10 cm end indicates the 
“worst bowel symptom” or “most intolerable.” Abdominal 
pain/discomfort intensity and VAS scores at visit 2 served as the 
baselines and the differences of pre- and post-treatment VAS 
scores at final visit were used for the secondary endpoints. At the 
final visit, subjects and investigators completed a global assess-
ment to the overall responses after trial, respectively. The global 
assessment was a 5-point scale, using the following definition: 0 
= worsened, 1 = no change, 2 = slightly improved, 3 = im-
proved and 4 = significantly improved. Throughout the study, 
the investigators closely monitored and recorded the probable oc-
currences of any adverse event (AE) after visit 2. All the AEs that 
occurred in subjects who took at least 1 dose of study medication 
were recorded in detail. The relationship of AE to study medi-
cation was also defined. 
Statistical Methods
All subjects who had consumed at least one dose of study 
medication and had at least one post-treatment evaluation on the 
primary endpoints were included in the intent-to-treat (ITT) 
population analysis. Furthermore, the per-protocol (PP) pop-
ulation consisted of all ITT subjects who did not take any vio-
lated medications and had completed at least 28 days of treat-
ment.
The primary endpoint was APDFSdifference or APDFS at 
baseline APDFS at 8th week. The primary hypothesis was: H0: 
μt-μs ≤ -0.35 Ha: μt-μs ＞ -0.35. While H0 means null- hy-
pothesis and Ha means alternative-hypothesis; μt means the 
APDFSdifference of the net OB response and μs denotes the 
APDFSdifference of the net mebeverine response. Treatment arm 
was declared as non-inferior if the difference in lower limit of 
97.5% one-sided confidence interval (CI) calculated by either t 
test or Wilcoxon rank sum test between treatments was greater 
than -0.35. Results were expressed as mean ± SD or median with 
inter-quartile range (IQR) when appropriate. Categorical differ-Otilonium Bromide to Treat IBS
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Figure. Trial overview including enroll-
ment, randomization and follow-up 
among the irritable bowel syndrome 
patients fulfilling Rome II definition. 
Dot lined squares mean the numbers of 
subject excluded from analysis. ITT, 
intention-totreat; OB, otilonium bromide;
PP, per-protocol.
Table 1. The Demographic Characteristics and Baseline Clinical Manifestations of Enrolled Irritable Bowel Syndrome Patients
Otilonium bromide (n = 59) Mebeverine (n = 58) P-value
Male gender (n [%])  31 (52.5)  26 (44.8) 0.461
Age (yr) 51.5 ± 16.5 54.4 ± 16.0 0.308
BMI (kg/m
2) 22.1 ± 2.9 22.5 ± 3.5 0.493
IBS duration (yr),   7.1 ± 7.7   8.6 ± 7.5 0.081
   Median (95% CI) 4.0 (3-7) 5.4 (4.6-10)
IBS subtype (n [%]) 0.140
   Diarrhea  34 (57.6)  42 (72.4)
   Constipation  22 (37.3)  12 (20.7)
   Mixed    3 (5.1)    4 (6.9)
Abdominal pain/discomfort frequency score
a 2.02 ± 0.99 2.08 ± 0.95 0.785
Abdominal pain/discomfort intensity score
a 1.20 ± 0.41 1.17 ± 0.47 0.599
Flatulence VAS score (0-10 cm) 5.26 ± 2.53 4.47 ± 3.06 0.523
Abdominal bloating VAS score (0-10 cm) 5.58 ± 3.01 4.75 ± 3.38 0.255
Satisfied stool frequency VAS score (0-10 cm) 6.17 ± 2.72 6.59 ± 2.88 0.373
aAbdominal pain/discomfort frequency score with 4-score severity divided as score 0 = none, score 1 = ≤ 3 episodes per week, score 2 = 4-7 episodes per week and
score 3 = ＞ 7 episodes per week.
BMI, body mass index; IBS, irritable bowel syndrome; VAS, visual analog scale using 10 cm scale.
Data are presented as mean ± SD.
ence was based on chi-square test or Fisher’s exact test when 
appropriate. The net changes of various parameters used for sec-
ondary endpoints were analyzed using either t test or Wilcoxon 
rank sum test to compare between treatments. Intra-assay differ-
ence was calculated using Wilcoxon signed rank test. Global as-
sessment by the investigators and subjects was analyzed using 
Mantel-Haenszel test to compare the differences between 
treatments. All the statistical tests were 2-tailed and the P-value 
less than 0.05 was considered significant.
Results
Totally, 132 IBS subjects fulfilling Rome II criteria gave in-
formed consent and were screened, and only 117 subjects were el-
igible to be randomized and treated (Figure). All these random-
ized subjects had consumed at least 1 dose of study medication. 
However, 16 subjects had violated ITT criteria and only 101 
subjects were enrolled in the ITT population including 49 in OB 
arm and 52 in mebeverine arm. Twenty subjects in the ITT pop-
ulation were excluded from the PP population based on our 
definition. Finally, 81 subjects (38 OB:43 mebeverine) were eli-
gible in the PP population. Table 1 depicts the demographic 
characteristics and baseline IBS symptoms of both arms. There 
were no differences in terms of age, gender, body mass index, 
IBS duration, proportions of IBS subtypes, abdominal pain/dis-
comfort severity etc. Overall, the treatment compliances of OB Full-Young Chang, et al
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Table 2. The Numbers of Patients With Net Changes in 8th Week
Evaluation Compared to Baseline Abdominal Pain/Discomfort 
Frequency Score (APDFS) Assessment in Irritable Bowel Synd-
rome Patients After Treatment
Otilonium bromide Mebeverine P-value
ITT (n = 49) ITT (n = 52)
   -3 score (%)       0 (0.0)       0 (0.0)
   -2 score (%)       5 (10.2)       3 (5.8)
   -1 score (%)       4 (8.2)       6 (11.5)
    0 (%)     21 (42.9)     20 (38.5)
+1 score (%)       8 (16.3)     16 (30.8)
+2 score (%)       8 (16.3)       4 (7.7)
+3 score (%)       3 (6.1)       3 (5.8)
Median (IQR)  0.00 (1.00)  0.00 (1.00) 0.890
95% CI (0.00; 1.00) (0.00; 1.00)
PP (n = 38) PP (n = 43)
   -3 score (%)       0 (0.0)       0 (0.0)
   -2 score (%)       2 (5.3)       2 (4.7)
   -1 score (%)      3 (7.9)       5 (11.6)
    0 (%)     16 (42.1)     19 (44.2)
+1 score (%)       8 (21.1)     11 (25.6)
+2 score (%)       7 (18.4)       4 (9.3)
+3 score (%)       2 (5.3)       2 (4.7)
Median (IQR)  0.00 (1.00)  0.00 (1.00) 0.479
95% CI (0.00; 1.00) (0.00; 1.00)
APDFS: abdominal pain/discomfort frequency score with 4-score severity 
divided as score 0 = none, score 1 = ≤ 3 episodes per week, score 2 = 4-7 
episodes per week and score 3 = ＞ 7 episodes per week; baseline: on day of 
randomization; score of net change: APDFS (baseline-8th week).
ITT, intention-to treat; IQR, inter-quartile range; PP, per-protocol.
Table 3. Commonly Reported Adverse Events Among the 
Irritable Bowel Syndrome Patients With at Least One Dose of 
Treatment
Event (%)
Otilonium bromide 
(n = 59)
Mebeverine
(n = 58)
P-value
Dry mouth 11 (18.6) 13 (22.4) 0.650
Nausea   8 (13.6)   0 (0.0) 0.006
Dizziness   6 (10.2)   1 (1.7) 0.110
Sore throat   4 (6.8)   4 (6.9) 1.000
Skin itching   2 (3.4)   3 (5.2) 0.680
Myalgia    2 (3.4)   0 (0.0) 0.490
Malaise    2 (3.4)   0 (0.0) 0.490
Headache   1 (1.7)   3 (5.2) 0.360
Abdominal pain   1 (1.7)   2 (3.4) 0.620
Insomnia    1 (1.7)   0 (0.0) 1.000
and mebeverine arms were 88.9% ± 13.0% and 90.4% ± 11.6%, 
respectively (NS), while the mean daily doses of using study 
drugs were 2.60 ± 0.47 and 2.66 ± 0.44 units, respectively 
(NS). On the other hand, the numbers of patient who consumed 
rescue agent at least once during the trial were 49 (100%) and 51 
(98.1%), respectively (NS). The total numbers of consumed lo-
peramide among both arms were 2.89 ± 0.32 and 3.05 ± 0.53, 
respectively (NS), whereas the numbers of consumed bisacodyl 
were 3.13 ± 0.97 and 2.93 ± 0.26, respectively (NS).
Briefly, about 40 % of subjects had APDFS improvement 
under either OB or mebeverine treatment based on ITT and PP 
populations (Table 2). Likewise, the mean reduced APDFS 
scores in the OB arm were 0.39 ± 1.32 (P = 0.056) and 0.55 ± 
1.20 (P = 0.011) based on ITT and PP populations, respec-
tively. However, the net APDFS reduced scores in the mebever-
ine arm were 0.40 ± 1.16 (P = 0.023) and 0.37 ± 1.11 (P = 
0.042) based on ITT and PP populations, respectively. None of 
the improved data showed statistically significant differences be-
tween 2 treatments. The lower bound of 95% CI of treatment dif-
ference was over the hypothesized set margin (-0.35) in both ITT 
and PP populations. Accordingly, we concluded that OB was at 
least comparable to mebeverine in reducing APDFS at final visit. 
Regarding the drug safety, 118 AEs had been reported including 
65 in OB and 53 in mebeverine. Among them, dry mouth was the 
most reported event in both treatments followed by nausea and 
dizziness particularly in OB treatment arm (Table 3). Most AEs 
were mild to moderate in nature (89.2% in OB; 88.7% in mebe-
verine), whereas 3 subjects (5.1%) in OB and 5 subjects (8.6%) 
in mebeverine were withdrawn owing to the intolerable AEs. 
Besides, 2 OB subjects (1 renal stone; 1 coronary heart disease) 
and 2 mebeverine subjects (1 amnesia; 1 herniated inter-vertebral 
disc) were hospitalized during the trial. All these serious AEs 
judged by the investigators were unlikely related to the study. On 
regarding the changes in terms of hematology, biochemistry, vital 
signs and physical examinations of 2 arms, there were no differ-
ences compared to the baselines.
With regard to the 2nd endpoints, Table 4 illustrates the net 
APDFS changes at 4th week evaluation. The mean APDFS re-
duced scores for OB and mebeverine were 0.12 ± 1.32 (P = 
0.545) and 0.31 ± 1.08 (P = 0.072), respectively, based on ITT 
populations without differences between 2 arms. The mean 
changed scores of PP populations were 0.24 ± 1.36 (P = 0.276) 
and 0.33 ± 1.04 (P = 0.70), respectively, without differences be-
tween 2 arms. The net changes of the patient numbers at final 
evaluation on the abdominal pain/discomfort intensity are illus-
trated in Table 5. Overall, the mean reduced intensity scores in 
OB arm were 0.41 ± 0.57 (P ＜ 0.001) and 0.45 ± 0.60 (P ＜ Otilonium Bromide to Treat IBS
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Table 4. The Numbers of Patients With Net Changes in 4th Week
Evaluation Compared to Baseline Abdominal Pain/Discomfort 
Frequency Score (APDFS) Assessment in Irritable Bowel Synd-
rome Patients Who Received Treatment
Otilonium bromide Mebeverine P-value
ITT (n = 49) ITT (n = 52)
   -3 score (%)       0 (0.0)       0 (0.0)
   -2 score (%)       6 (12.2)       4 (7.7)
   -1 score (%)       9 (18.4)       2 (3.8)
    0 (%)     17 (34.7)     28 (53.8)
+1 score (%)       9 (18.4)     12 (23.1)
+2 score (%)       6 (12.2)       4 (7.7)
+3 score (%)       2 (4.1)       2 (3.8)
Median (IQR)  0.00 (2.00)  0.00 (1.00) 0.365
95% CI (0.00; 0.00) (0.00; 0.00)
PP (n = 38) PP (n = 43)
   -3 score (%)       0 (0.0)       0 (0.0)
   -2 score (%)       4 (10.5)       3 (7.0)
   -1 score (%)       7 (18.4)       2 (4.7)
    0 (%)     13 (34.2)      22 (51.2)
+1 score (%)       6 (15.8)     11 (25.6)
+2 score (%)       6 (15.8)       4 (9.3)
+3 score (%)       2 (5.3)       1 (2.3)
Median (IQR)  0.00 (2.00)  0.00 (1.00) 0.588
95% CI (0.00; 1.00) (0.00; 1.00)
APDFS: abdominal pain/discomfort frequency score with 4-score severity 
divided as score 0 = none, score 1 = ≤ 3 episodes per week, score 2 = 4-7 
episodes per week, and score 3 = ＞ 7 episodes per week; baseline: on day of 
randomization; score of net change: APDFS (baseline-4th week).
Abbreviations as in Table 2.
Table 5. The Numbers of Patients With Net Changes in 8th Week
Evaluation Compared to Baseline Abdominal Pain/Discomfort 
Intensity Scored in the Irritable Bowel Syndrome Patients After 
Treatment
Otilonium bromide Mebeverine P-value
ITT (n = 49) ITT (n = 52)
   -3 score (%)       0 (0.0)       0 (0.0)
   -2 score (%)       0 (0.0)       0 (0.0)
   -1 score (%)       0 (0.0)       0 (0.0)
    0 (%)     31 (63.3)     39 (75.0)
+1 score (%)     16 (32.7)       9 (17.3)
+2 score (%)       2 (4.1)       4 (7.7)
+3 score (%)       0 (0.0)       0 (0.0)
Median (IQR)  0.00 (1.00)  0.00 (0.50) 0.289
95% CI (0.00; 1.00) (0.00; 0.00)
PP (n = 38) PP (n = 43)
   -3 score (%)       0 (0.0)       0 (0.0)
   -2 score (%)       0 (0.0)       0 (0.0)
   -1 score (%)       0 (0.0)       0 (0.0)
    0 (%)     23 (60.5)     33 (76.7)
+1 score (%)     13 (34.2)       7 (16.3)
+2 score (%)       2 (5.3)       3 (7.0)
+3 score (%)       0 (0.0)       0 (0.0)
Median (IQR)  0.00 (1.00)  0.00 (0.00) 0.162
95% CI (0.00; 1.00) (0.00; 0.00)
Four-score of abdominal pain/discomfort intensity: score 0 = absent, score 1 = 
mild, score 2 = moderate and score 3 = severe; baseline: on day of rando-
mization; score of net change: Abdominal pain/discomfort intensity score 
(baseline-8th week).
Abbreviations as in Table 2.
Table 6. The 10 cm Visual Analog Scale Scored Bowel Symptoms
of Irritable Bowel Syndrome Patients After Either Otilonium 
Bromide or Mebeverine Treatment
Symptom
OB Mebeverine
ITT 
(n = 49)
PP 
(n = 38)
ITT 
(n = 52)
PP 
(n = 43)
Flatulence
   Baseline (visit 2) 5.6 (3.6)
a 5.3 (3.9)
b 3.6 (5.4)
c 3.0 (5.4)
d
   Final 2.0 (2.7)
a 1.6 (2.8)
b 2.0 (4.1)
c 1.6 (4.4)
d
Abdominal bloating
   Baseline (visit 2) 5.1 (4.2)
e 4.4 (3.9)
f 4.7 (6.6)
g 4.5 (7.0)
h
   Final 1.7 (3.3)
e 1.3 (3.2)
f 1.3 (4.6)
g 1.3 (4.8)
h
Satisfied stool frequency
   Baseline (visit 2) 5.0 (5.0)
i 4.2 (4.2)
j 4.8 (5.3)
k 4.6 (5.5)
l
   Final 1.5 (2.9)
i 1.4 (2.4)
j 1.7 (3.9)
k 1.8 (4.0)
l
OB, otilonium bromide; ITT, intention-to-treat; PP, per-protocol. 
Results are median (inter-quartile range). Inter-assay difference: 
a-c,e-lP ＜ 0.001,
dP = 0.003.
0.001), and the mean reduced intensity scores in mebeverine arm 
were 0.33 ± 0.62 (P = 0.001) and 0.30 ± 0.60 (P = 0.004), re-
spectively, based on ITT and PP populations. None of the above 
data showed statistical difference between 2 arms. Other changes 
of IBS symptoms in terms of flatulence, abdominal bloating and 
satisfied stool frequency are depicted in Table 6. Briefly, these 
evaluated bowel symptoms had marked improvement after both 
treatments, on either ITT or PP analysis, while the changes in 
abdominal bloating and satisfied stool frequency were similar in 
both groups (data were not shown). Table 7 denotes the global 
symptom assessments filled at final visit. Regarding ITT pop-
ulation, the proportions of at least slight improvement of OB and 
mebeverine evaluated by the investigators were 87.8% and 
76.9%, respectively (NS), whereas those of PP population were 
86.8% and 74.4%, respectively (NS). By the patients, the pro-
portions of subjects with at least slight improvement of OB and 
mebeverine were 89.8% and 78.8% (P ＜ 0.05), respectively, in Full-Young Chang, et al
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Table 7. Global Assessment Respectively Filled by the Investigat-
ors and Irritable Bowel Syndrome Patients at the Final Visit After 
Treatment
Otilonium 
bromide
Mebeverine P-value
a
Investigator assessment  ITT (n = 49)  ITT (n = 52)  0.089
    Worsen       1 (2.0)       0 (0.0)
    No change       5 (10.2)     12 (23.1)
    Slightly improved     11 (22.4)     14 (26.9)
    Improved      15 (30.6)     14 (26.9)
    Markedly improved      17 (34.7)     12 (23.1)
Investigator assessment    PP (n = 38)    PP (n = 43)  0.071
    Worsen        1 (2.6)       0 (0.0)
    No change        4 (10.5)     11 (25.6)
    Slightly improved        7 (18.4)     10 (23.3)
    Improved      11 (28.9)     12 (27.9)
    Markedly improved     15 (39.5)     10 (27.9)
Patient assessment   ITT (n = 49)  ITT(n = 52)  0.046
    Worsen       0 (0.0)       0 (0.0)
    No change        5 (10.2)     11 (21.2)
    Slightly improved      14 (28.6)     18 (34.6)
    Improved      18 (36.7)     16 (30.8)
    Markedly improved      12 (24.5)       7 (13.5)
Patient assessment     PP (n = 38)    PP (n = 43)  0.042
    Worsen        0 (0.0)       0 (0.0)
    No change        5 (13.2)       9 (20.9)
    Slightly improved        8 (21.1)     16 (37.2)
    Improved      15 (39.5)     12 (27.9)
    Markedly improved      10 (26.3)       6 (14.0)
ITT, intention-to-treat; PP, per-protocol.
Data are presented as n (%). 
aBased on Mantel-Haenszel test.
the ITT populations and 86.8% and 79.1% (P ＜ 0.05), re-
spectively, in the PP populations.
Discussion
M e b e v e r i n e  h a s  l o n g  b e e n  m a r k e t e d  i n  A s i a  a s  a n  a n t i -
spasmodic to treat IBS for decades. Using it as an active-con-
trolled agent, our study based on the primary endpoint mainly in-
dicated that OB was as effective as mebeverine in improving the 
APDFS of represented IBS main symptoms during an 8-week 
period treatment. Our previous study pointed out that mebever-
ine was effective in reducing BM frequency and stool consistency 
for the diarrhea-predominant IBS patients but no obvious effect 
for abdominal pain.
20 Besides, a meta-analysis also indicates that 
mebeverine has no global effect to treat IBS abdomen pain com-
pared to the placebo although it is tolerable without obvious side 
effects.
21 It is believed that placebo does exhibit an amazing effi-
cacy to treat IBS patients with range of 20%-50%.
3,22 According-
ly, an agent shown superior to placebo in treating IBS should be 
obtained from a large-scaled study or meta-analysis, eg, the tega-
serod trials.
23 Owing to the comparable efficacy to placebo, it is 
likely that many mebeverine studies including our previous trial 
do not confirm its perfect efficacy to treat abdominal pain, one of 
the IBS main symptoms.
Since abdominal pain/discomfort has been a very subjective 
complaint to IBS patients, it would be difficult to quantify it us-
ing any reliable parameters.
2 In addition, as the abdominal pain 
scales in many trials are often recorded by the recalled manner, it 
is unknown whether any pain character recording does reflect the 
true sensation on the assigned visits after several days or weeks. 
In order to diminish this drawback, we employed the APDFS 
based on recorded pain frequency in the distributed diary card 
and tried to describe the pain character more objectively for the 
primary endpoint. Based on APDFS, our primary objective did 
confirm a fair but not perfect efficacy of OB comparable to mebe-
verin in reducing the IBS abdominal pain frequency. In addition, 
another parameter of abdominal pain intensity score also con-
firmed the at least equal OB efficacy to mebeverine. The rationale 
of using antispasmodics to treat IBS is likely based on the ob-
servations of disturbed GI motility among these patients.
2,4,12,24 
Actually, bowel dysmotility does result in functional abdominal 
pain among the IBS patients.
3,25 Unfortunately, the central sensa-
tion of visceral pain is not uniquely related to the disturbed GI 
motility. It means that many biopsychosocial factors like mind, 
environmental factors, visceral hypersensitivity and brain-gut in-
teraction may modify the final pain perception for the patients 
with functional GI disorders including IBS.
1,26 Because of the ex-
cessive confounding factors in modifying the central pain sensa-
tion with heterogeneity in published studies, many antispasmodic 
trials cannot conclude a perfect efficacy to treat the abdominal 
pain, while the comparable placebo does achieve a similar 
efficacy. Sometimes, only the meta-analysis can summarize its 
possible efficacy.
3,14
Among researches on the OB efficacy on IBS patients, an 
early small-scaled study conducted in Italy indicated that OB did 
reduce the abdominal pain and bloating but no differences were 
observed from placebo.
27 Consequently, a large-scaled placebo 
controlled trial among the Italian IBS patients indicated that the 
reduced episode of abdominal pain was higher in OB treated pa-
tients (55.3%) than in placebo group (39.9%), while the fair effi-
cacies were observed for the abdominal distension and general 
well-being among those on OB treatment.
17 Nevertheless, the au-Otilonium Bromide to Treat IBS
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thors did not particularly address the probable side effects in that 
trial. A review based on 4 OB trials then concluded that OB may 
r e l i e v e  I B S  s y m p t o m s  w i t h  a  r e l a t i v e  r i s k  o f  0 . 5 5  ( 9 5 %  C I ,  
0.310-0.097) over placebo.
28 Currently, OB has been recom-
mended as an effective and safe agent to treat IBS abdominal pain 
and distension, particularly in reducing diarrhea, whereas the 
most addressed side effect is urticaria.
29 In addition to the reduc-
tion in IBS abdominal pain, our OB study did confirm the similar 
efficacies including improved abdomen bloating, flatulence, sat-
isfied BM frequency and global assessments.
Apart from blocking the calcium ion influx through L-type 
voltage operated calcium channels in GI smooth muscle cells, 
OB pharmacologically inhibited central/peripheral tachykinin-2 
receptor which not only showed antispasmodic activity but also 
reduced the afferent transmission of sensory signals from the pe-
riphery to central nervous system.
15,30 It is of interest whether this 
tachykinin receptor blocking ability in the afferent transmission 
reduce the IBS pain severity or not. In fact, a clinical trial did 
confirm that OB enhanced the perceptual threshold of IBS sub-
jects during the anorectal balloon distension.
31 Since visceral hy-
persensitivity has been one of the main components of the IBS 
pathogeneses,
2,3 OB is therefore possible to treat the IBS main 
symptom apart from its antispasmodic effect. In addition, OB al-
so shows a high affinity in binding to various muscarinic receptor 
subtypes in terms of M1, M2, M3, M4 and M5, respective-
ly.
32,33 Owing to its potent muscarinic blockade, OB not only ex-
hibit an antispasmodic but also antisecretory ability through M3 
sub-receptor which is abundantly found in human colonic crypt 
cells to mediate secretion coupled with calcium channels.
33 It is 
why OB can improve the stool consistency.
18,29 Furthermore, 
both M1 and M3 sub-receptors have been the main targets of 
nervous impulse to mediate salivary gland secretion.
34 Because 
OB also targets on these muscarinic sub-receptors, the most ob-
served AE of dry mouth among our trial was likely the un-
expected OB effect on the salivary glands. Antimuscarinic drugs 
used to treat overactive bladder are occasionally associated with 
central nervous system side effects, eg, cognitive dysfunction, 
dizziness, fatigue etc.
35 Nausea and dizziness reported under OB 
treatment were suggested to result from the central antimus-
carinic effect. However, other trials did not report these side 
effects.
The limitation of our OB study has been the single center 
and small-scaled trial. Usually, the small-scaled study may have 
inadequate sample size and study power to achieve an expected 
result, whereas single center trial sometimes leads to study bias.
36 
Clinically, functional GI disordered subjects are often not very 
satisfactory to the recommended treatments because of the asso-
ciated somatic complaints, functional disturbances existed in oth-
er organ systems, psychiatric disorders and social impacts.
2,3,13,37 
Our enrolled subjects almost had consumed rescue agents during 
the trial. It is likely that they were very to concerned about the ab-
normal BM and had no confidence in relieving the abnormal 
BM activity even been informed of an active treatment. Since this 
is the first OB trial conducted in Asia, it remains uncertain 
whether OB could achieve an ideal efficacy to treat IBS patients 
comparable to that of European study.
17 Concerning its major 
antimuscarininc side effects, a large-scaled trial and post-market-
ing surveillance are recommended based on our preliminary 
results. In conclusions, OB effectively improved the IBS symp-
toms in terms of abdominal pain, flatulence, abdominal bloating, 
satisfied stool frequency and global assessment in Asian patients. 
Unfortunately, obvious side effects like dry mouth, nausea and 
dizziness were also observed. A large-scaled trial and post-mar-
keting surveillance are recommended to confirm its true efficacy 
and safety.
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